Literature DB >> 22923695

On the mechanism of CD47 targeting in cancer.

Xi Wen Zhao, Hanke L Matlung, Taco W Kuijpers, Timo K van den Berg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22923695      PMCID： PMC3479482          DOI： 10.1073/pnas.1209265109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  5 in total

1.  Is targeting of CD47-SIRPα enough for treating hematopoietic malignancy?

Authors:  Xi Wen Zhao; Taco W Kuijpers; Timo K van den Berg
Journal:  Blood       Date:  2012-05-03       Impact factor: 22.113

2.  CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction.

Authors:  Xi Wen Zhao; Ellen M van Beek; Karin Schornagel; Hans Van der Maaden; Michel Van Houdt; Marielle A Otten; Pascal Finetti; Marjolein Van Egmond; Takashi Matozaki; Georg Kraal; Daniel Birnbaum; Andrea van Elsas; Taco W Kuijpers; Francois Bertucci; Timo K van den Berg
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-31       Impact factor: 11.205

3.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.

Authors:  Stephen B Willingham; Jens-Peter Volkmer; Andrew J Gentles; Debashis Sahoo; Piero Dalerba; Siddhartha S Mitra; Jian Wang; Humberto Contreras-Trujillo; Robin Martin; Justin D Cohen; Patricia Lovelace; Ferenc A Scheeren; Mark P Chao; Kipp Weiskopf; Chad Tang; Anne Kathrin Volkmer; Tejaswitha J Naik; Theresa A Storm; Adriane R Mosley; Badreddin Edris; Seraina M Schmid; Chris K Sun; Mei-Sze Chua; Oihana Murillo; Pradeep Rajendran; Adriel C Cha; Robert K Chin; Dongkyoon Kim; Maddalena Adorno; Tal Raveh; Diane Tseng; Siddhartha Jaiswal; Per Øyvind Enger; Gary K Steinberg; Gordon Li; Samuel K So; Ravindra Majeti; Griffith R Harsh; Matt van de Rijn; Nelson N H Teng; John B Sunwoo; Ash A Alizadeh; Michael F Clarke; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-26       Impact factor: 11.205

4.  CD47, a ligand for the macrophage fusion receptor, participates in macrophage multinucleation.

Authors:  X Han; H Sterling; Y Chen; C Saginario; E J Brown; W A Frazier; F P Lindberg; A Vignery
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

5.  Integrin-associated protein is a ligand for the P84 neural adhesion molecule.

Authors:  P Jiang; C F Lagenaur; V Narayanan
Journal:  J Biol Chem       Date:  1999-01-08       Impact factor: 5.157
  5 in total
  13 in total

1.  On the mechanism and benefit of siRNA-mediated targeting of CD47 in cancer.

Authors:  Xiwen Zhao; Hanke Matlung; Taco W Kuijpers; Timo K van den Berg
Journal:  Mol Ther       Date:  2013-10       Impact factor: 11.454

Review 2.  Macrophage engulfment of a cell or nanoparticle is regulated by unavoidable opsonization, a species-specific 'Marker of Self' CD47, and target physical properties.

Authors:  Nisha G Sosale; Kyle R Spinler; Cory Alvey; Dennis E Discher
Journal:  Curr Opin Immunol       Date:  2015-07-13       Impact factor: 7.486

3.  Therapeutic targeting of the thrombospondin-1 receptor CD47 to treat liver cancer.

Authors:  David D Roberts; Sukhbir Kaur; David R Soto-Pantoja
Journal:  J Cell Commun Signal       Date:  2015-03-18       Impact factor: 5.782

Review 4.  Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47.

Authors:  David R Soto-Pantoja; Erica V Stein; Natasha M Rogers; Maryam Sharifi-Sanjani; Jeffrey S Isenberg; David D Roberts
Journal:  Expert Opin Ther Targets       Date:  2012-10-27       Impact factor: 6.902

Review 5.  Functions of Thrombospondin-1 in the Tumor Microenvironment.

Authors:  Sukhbir Kaur; Steven M Bronson; Dipasmita Pal-Nath; Thomas W Miller; David R Soto-Pantoja; David D Roberts
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 6.208

Review 6.  Insights into CD47/SIRPα axis-targeting tumor immunotherapy.

Authors:  Xuyao Zhang; Jiajun Fan; Dianwen Ju
Journal:  Antib Ther       Date:  2018-08-28

7.  CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer.

Authors:  Kazumichi Yoshida; Hironori Tsujimoto; Kouji Matsumura; Manabu Kinoshita; Risa Takahata; Yusuke Matsumoto; Shuichi Hiraki; Satoshi Ono; Shuhji Seki; Junji Yamamoto; Kazuo Hase
Journal:  Cancer Med       Date:  2015-06-16       Impact factor: 4.452

8.  CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models.

Authors:  Ji-Feng Xu; Xiao-Hong Pan; Shui-Jun Zhang; Chen Zhao; Bin-Song Qiu; Hai-Feng Gu; Jian-Fei Hong; Li Cao; Yu Chen; Bing Xia; Qin Bi; Ya-Ping Wang
Journal:  Oncotarget       Date:  2015-09-15

9.  CD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLCγ1 activation: evidence from mice and humans.

Authors:  Ana-Carolina Martinez-Torres; Claire Quiney; Tarik Attout; Heloïse Boullet; Linda Herbi; Laura Vela; Sandrine Barbier; Danielle Chateau; Elise Chapiro; Florence Nguyen-Khac; Frédéric Davi; Magali Le Garff-Tavernier; Roba Moumné; Marika Sarfati; Philippe Karoyan; Hélène Merle-Béral; Pierre Launay; Santos A Susin
Journal:  PLoS Med       Date:  2015-03-03       Impact factor: 11.069

10.  Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo.

Authors:  Michael Zhang; Gregor Hutter; Suzana A Kahn; Tej D Azad; Sharareh Gholamin; Chelsea Y Xu; Jie Liu; Achal S Achrol; Chase Richard; Pia Sommerkamp; Matthew Kenneth Schoen; Melissa N McCracken; Ravi Majeti; Irving Weissman; Siddhartha S Mitra; Samuel H Cheshier
Journal:  PLoS One       Date:  2016-04-19       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.